|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||84.37 - 84.92|
|52-week range||77.04 - 98.52|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||21.52|
|Forward dividend & yield||3.20 (3.77%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||N/A|
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term.